MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/09546634.2026.2707697

Медицинская библиотека · The Journal of dermatological treatment · 2026

Effectiveness of bimekizumab according to previous biologic exposure in patients with plaque psoriasis: a multicenter real-world study.

Trovato Emanuele, Di Cesare Antonella, Panduri Salvatore, Pescitelli Leonardo, Ricceri Federica, Lo Conte Sofia, Brandini Luca, Cuccia Aldo, Romanelli Marco, Rubegni Pietro, Prignano Francesca

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

OBJECTIVES

Bimekizumab, a dual interleukin (IL)-17A/IL-17F inhibitor, has demonstrated clinical efficacy in clinical trials. However, real-world evidence comparing outcomes according to previous biologic exposure remains limited. We evaluated the effectiveness of bimekizumab in biologic-naïve and biologic-experienced patients with plaque psoriasis, including high-impact body areas.

METHODS

We retrospectively analyzed 98 patients treated with bimekizumab (23 biologic-naïve, 75 biologic-experienced). Outcomes included Psoriasis Area and Severity Index (PASI), PASI90 and PASI100 response rates, and Physician Global Assessment (PGA) scores for scalp, nail, genital, palmoplantar, and pretibial psoriasis. Biologic-experienced patients were further stratified by the number of prior biologics.

RESULTS

Despite higher baseline PASI values (18.04 vs. 13.29; p = 0.021), biologic-naïve patients achieved significantly faster responses. At week 4, PASI reduction (85.5% vs. 62.5%; p < 0.001), PASI90 (50.0% vs. 13.3%; p = 0.001), and PASI100 (50.0% vs. 11.7%; p = 0.001) were significantly higher in biologic-naïve patients. Similar findings were observed in high-impact areas. Differences persisted through week 16 but disappeared from week 24 onward. Nevertheless, biologic-naïve patients maintained numerically higher response rates throughout follow-up. Previous biologic burden did not compromise long-term outcomes.

CONCLUSIONS

Bimekizumab showed sustained effectiveness regardless of prior biologic exposure. Nevertheless, biologic-naïve patients achieved faster and deeper responses, supporting earlier use of bimekizumab to maximize treatment benefit.

Для цитирования: Trovato Emanuele, Di Cesare Antonella, Panduri Salvatore, Pescitelli Leonardo, Ricceri Federica, Lo Conte Sofia, Brandini Luca, Cuccia Aldo, Romanelli Marco, Rubegni Pietro, Prignano Francesca. Effectiveness of bimekizumab according to previous biologic exposure in patients with plaque psoriasis: a multicenter real-world study.. The Journal of dermatological treatment. 2026. DOI: 10.1080/09546634.2026.2707697.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.